Da‐Peng Dai

1.6k total citations
87 papers, 1.2k citations indexed

About

Da‐Peng Dai is a scholar working on Pharmacology, Molecular Biology and Oncology. According to data from OpenAlex, Da‐Peng Dai has authored 87 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pharmacology, 30 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Da‐Peng Dai's work include Pharmacogenetics and Drug Metabolism (49 papers), Drug Transport and Resistance Mechanisms (12 papers) and Eicosanoids and Hypertension Pharmacology (10 papers). Da‐Peng Dai is often cited by papers focused on Pharmacogenetics and Drug Metabolism (49 papers), Drug Transport and Resistance Mechanisms (12 papers) and Eicosanoids and Hypertension Pharmacology (10 papers). Da‐Peng Dai collaborates with scholars based in China, United States and Japan. Da‐Peng Dai's co-authors include Jian‐Ping Cai, Guoxin Hu, Shuanghu Wang, Peiwu Geng, Jianping Cai, Samuel H. Wilson, Julie K. Horton, Jie Cai, Rajendra Prasad and Melike Çağlayan and has published in prestigious journals such as Nature Communications, Scientific Reports and The FASEB Journal.

In The Last Decade

Da‐Peng Dai

85 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Da‐Peng Dai China 19 587 439 271 188 128 87 1.2k
Miroslav Dostálek United States 22 367 0.6× 542 1.2× 226 0.8× 181 1.0× 176 1.4× 45 1.6k
Alvin Gomez Sweden 15 783 1.3× 660 1.5× 489 1.8× 195 1.0× 106 0.8× 18 1.7k
R. Foti United States 21 680 1.2× 408 0.9× 373 1.4× 139 0.7× 83 0.6× 51 1.3k
Catherine K. Yeung United States 21 449 0.8× 578 1.3× 268 1.0× 109 0.6× 53 0.4× 41 1.6k
Xiaoping Chen China 21 574 1.0× 335 0.8× 245 0.9× 255 1.4× 62 0.5× 45 1.3k
Mats Hidestrand United States 26 876 1.5× 549 1.3× 439 1.6× 183 1.0× 139 1.1× 40 1.8k
Mark P. Grillo United States 23 528 0.9× 371 0.8× 226 0.8× 240 1.3× 71 0.6× 47 1.4k
Hidetaka Kamimura Japan 24 651 1.1× 423 1.0× 676 2.5× 231 1.2× 107 0.8× 98 1.6k
Georgia Ragia Greece 19 441 0.8× 216 0.5× 205 0.8× 106 0.6× 219 1.7× 62 1.1k
Päivi Taavitsainen Finland 18 722 1.2× 226 0.5× 318 1.2× 184 1.0× 103 0.8× 26 1.1k

Countries citing papers authored by Da‐Peng Dai

Since Specialization
Citations

This map shows the geographic impact of Da‐Peng Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Da‐Peng Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Da‐Peng Dai more than expected).

Fields of papers citing papers by Da‐Peng Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Da‐Peng Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Da‐Peng Dai. The network helps show where Da‐Peng Dai may publish in the future.

Co-authorship network of co-authors of Da‐Peng Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Da‐Peng Dai. A scholar is included among the top collaborators of Da‐Peng Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Da‐Peng Dai. Da‐Peng Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Dongxu, Yang An, Xiaoyue Zhou, et al.. (2025). Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants. British Journal of Clinical Pharmacology. 91(9). 2736–2744. 1 indexed citations
2.
3.
Zhang, Li‐Qun, Xinyue Li, Lianguo Chen, et al.. (2024). Genetic variants, haplotype determination, and function of novel alleles of CYP2B6 in a Han Chinese population. Heliyon. 10(7). e28952–e28952. 1 indexed citations
4.
Zhang, Qing, Shuanghu Wang, Lili Zou, et al.. (2023). Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects. Frontiers in Endocrinology. 14. 6 indexed citations
5.
Wang, Shuanghu, Mengming Xia, Yu Wang, et al.. (2023). Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS. Thoracic Cancer. 14(14). 1276–1285. 1 indexed citations
6.
Zhou, Quan, Pengjiao Hou, Yu Wang, et al.. (2023). Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo. Frontiers in Pharmacology. 14. 1204649–1204649. 1 indexed citations
7.
Wang, Dongxu, Qing Zhang, Xiaoyue Zhou, et al.. (2023). Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants. European Journal of Clinical Pharmacology. 79(10). 1315–1320.
8.
Wu, Qingjun, Shuanghu Wang, Jian Liu, et al.. (2022). Polymorphic mutations in the polb gene promoter and their impact on transcriptional activity. Thoracic Cancer. 13(6). 853–857. 2 indexed citations
9.
Chen, Hao, et al.. (2022). An Unusual Incessant Narrow-Wide Complex Polymorphic Tachycardia. JACC. Clinical electrophysiology. 8(10). 1337–1339. 4 indexed citations
10.
Chen, Feifei, Hui Jiang, Shuanghu Wang, et al.. (2020). <p>In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine</p>. Drug Design Development and Therapy. Volume 14. 4815–4824. 10 indexed citations
11.
Wu, Qingjun, Hui Jiang, Shuanghu Wang, et al.. (2020). Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats. Thoracic Cancer. 11(10). 2775–2781. 13 indexed citations
12.
Fang, Ping, et al.. (2017). Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro. Pharmacology. 100(1-2). 91–97. 5 indexed citations
13.
Liang, Bingqing, Yali Zhou, Xiangyü Li, et al.. (2016). Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on theN-demethylation of amitriptylinein vitro. Pharmaceutical Biology. 54(11). 2475–2479.
14.
Hu, Jihong, et al.. (2015). Effect of <b><i>CYP2C9</i></b> Genetic Polymorphism in a Chinese Population on the Metabolism of Mestranol in vitro. Pharmacology. 95(5-6). 218–223. 7 indexed citations
15.
Dai, Da‐Peng, et al.. (2015). In vitrofunctional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population. Xenobiotica. 45(11). 1030–1035. 14 indexed citations
16.
17.
Zeng-shou, Wang, Liping Yang, Da‐Peng Dai, et al.. (2015). In Vitro and In Vivo Characterization of 13 CYP2C9 Allelic Variants Found in Chinese Han Population. Drug Metabolism and Disposition. 43(4). 561–569. 12 indexed citations
18.
Wang, Zhenhe, et al.. (2015). Effects of 24 CYP2D6 Variants Found in the Chinese Population on the Metabolism of Risperidone. Pharmacology. 96(5-6). 290–295. 8 indexed citations
19.
Liang, Bingqing, Hao Wang, Zhenhe Wang, et al.. (2015). Effect of CYP2D6 variants on venlafaxine metabolism in vitro. Xenobiotica. 46(5). 424–429. 16 indexed citations
20.
Zhang, Liqun, Dongge Liu, Jing Lin, et al.. (2011). Oxidative Damage to RNA and Expression Patterns of MTH1 in the Hippocampi of Senescence-Accelerated SAMP8 Mice and Alzheimer’s Disease Patients. Neurochemical Research. 36(8). 1558–1565. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miroslav Dostálek Breakdown of academic impact, for papers by Alvin Gomez Breakdown of academic impact, for papers by R. Foti Breakdown of academic impact, for papers by Catherine K. Yeung Breakdown of academic impact, for papers by Xiaoping Chen Breakdown of academic impact, for papers by Mats Hidestrand Breakdown of academic impact, for papers by Mark P. Grillo Breakdown of academic impact, for papers by Hidetaka Kamimura Breakdown of academic impact, for papers by Georgia Ragia Breakdown of academic impact, for papers by Päivi Taavitsainen
Rankless by CCL
2026